NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS

1 . A compound of formula (I),

stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (I) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (I); wherein,

X, Y and Z are each independently selected from N or CR b , wherein R b is selected from hydrogen, halogen or alkyl; with a proviso that when X and Y are each independently N, Z is —CR b and when Y and Z are each independently N, X is —CR b ;

A is a 3 to 7 membered cycloalkyl ring;

B is an optionally substituted group selected from alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or —NR 2 R 3 , wherein one or more optional substituents on B are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, alkoxy, cycloalkyl, —CO-alkyl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f , —(CH 2 ) n SO 2 NR c R d , aryl, heteroaryl or heterocyclyl;

R 1 is selected from hydrogen or alkyl;

R 2 and R 3 are each independently selected from hydrogen, —(CH 2 ) n -hydroxy, —(CH 2 ) n -halogen, and an optionally substituted group selected from alkyl, —(CH 2 ) n -cycloalkyl, —(CH 2 ) n -heterocyclyl, —(CH 2 ) n -aryl or —(CH 2 ) n -heteroaryl, wherein one or more optional substituents on R 2 and R 3 are each independently selected from halogen, cyano, hydroxy, alkyl, cycloalkyl, alkoxy, —CO-alkyl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f , —(CH 2 ) n SO 2 NR c R d , aryl, heteroaryl or heterocyclyl; or

R 2 and R 3 optionally combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered heterocyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO 2 or CO, wherein one or more optional substituents on the heterocyclic ring are selected from halogen, hydroxy, alkoxy, alkyl, cycloalkyl or —CO-alkyl;

R 4 is hydrogen or an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, hydroxy, cyano, alkyl, —(CH 2 ) n —OH, cycloalkyl, alkoxy or —CO-alkyl;

R a is selected from cyano, —(CH 2 ) n —OH, —(CH 2 ) n -alkoxy, alkyl, aryl, —NH-aryl, heteroaryl, —(CH 2 ) n CO-alkyl, —(CH 2 ) n COOR c , —(CH 2 ) n CONR d R e , —(CH 2 ) n SO 2 R f , or —(CH 2 ) n SO 2 NR c R d ;

R c is selected from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;

R d and R e are each independently selected from hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, alkoxy, aryl, heteroaryl or heterocyclyl, wherein one or more optional substituents on R d and R e are each independently selected from halogen, hydroxy or alkyl;

R f is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and

n is an integer from 0 to 2.

2 . The compound as claimed in claim 1 , having the formula (II)

stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (II) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (II)

3 . The compound as claimed in claim 1 , having the formula (III)

stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (III) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (III).

4 . The compound as claimed in claim 3 , wherein

A is selected from cyclopropyl, cyclobutyl or cyclopentyl;

R 1 is hydrogen;

R 2 is selected from hydrogen or —(CH 2 ) n -cycloalkyl;

R 3 is selected from hydrogen, —(CH 2 ) n -hydroxy, —(CH 2 ) n -halogen, and an optionally substituted group selected from alkyl, —(CH 2 ) n -cycloalkyl, —(CH 2 ) n -heterocyclyl, —(CH 2 ) n -aryl or —(CH 2 ) n -heteroaryl; wherein one or more optional substituents on R 2 and R 3 are each independently selected from halogen, cyano, hydroxy, alkyl, cycloalkyl, alkoxy, —CO-alkyl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f , —(CH 2 ) n SO 2 NR c R d , aryl, heteroaryl or heterocyclyl;

R 4 is an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;

R a is selected from cyano, alkyl, —(CH 2 ) n —OH, —(CH 2 ) n -alkoxy, —CO-alkyl, heteroaryl, —(CH 2 ) n COOR c , —(CH 2 ) n CONR d R e , —(CH 2 ) n SO 2 R f or —(CH 2 ) n SO 2 NR c R d ;

R b is selected from hydrogen or alkyl;

R c is selected from hydrogen or alkyl;

R d and R e are each independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen;

R f is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and

n is an integer from 0 to 2.

5 . The compound as claimed in claim 4 , wherein

R 3 is selected from hydrogen, alkyl, —(CH 2 ) n -cycloalkyl, and optionally substituted groups selected from —(CH 2 ) n —OH, —(CH 2 ) n -heterocyclyl, —(CH 2 ) n -aryl, —(CH 2 ) n -heteroaryl, wherein the optional substituents on R 3 are selected from halogen, —CH 2 —OH, alkyl, aryl, —(CH 2 ) n SO 2 NR c R d or —(CH 2 ) n SO 2 R f ;

R 4 is selected from an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, alkyl or alkoxy;

R a is selected from cyano, alkyl, —(CH 2 ) n —OH, —(CH 2 ) n -alkoxy, —CO-alkyl, heteroaryl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f or —(CH 2 ) n SO 2 NR c R d ;

R c is selected from hydrogen or alkyl, and

R d and R e are each independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen.

6 . The compound as claimed in claim 3 , wherein

R 2 and R 3 combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered heterocyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO 2 or CO, wherein one or more optional substituents on the heterocyclic ring fowled may be selected from halogen, hydroxyl, alkoxy, alkyl, cycloalkyl or —CO-alkyl;

R 4 is an optionally substituted group selected from cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;

R a is selected from cyano, alkyl, —(CH 2 ) n —OH, —(CH 2 ) n -alkoxy, —CO-alkyl, heteroaryl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f or —(CH 2 ) n SO 2 NR c R d ;

R c is selected from hydrogen or alkyl;

R d and R e are each independently selected from hydrogen, alkyl or alkoxy;

R f is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and

n is an integer from 0 to 2.

7 . The compound as claimed in claim 6 , wherein

R 2 and R 3 combine with the nitrogen atom, to which they are attached, to form an optionally substituted morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, dioxo-thiomorpholinyl, wherein one or more optional substituents on the heterocyclic ring formed may be selected from halogen, hydroxy, alkoxy, alkyl or —CO-alkyl;

R 4 is an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, alkyl or alkoxy;

R a is selected from —COOR c or —CONR d R e ;

R c is selected from hydrogen or alkyl; and

R d and R e are independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen.

8 . The compound as claimed in claim 1 , having the formula (IV),

stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (IV) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (IV).

9 . The compound as claimed in claim 8 , wherein

R 1 is hydrogen;

A is selected from cyclopropyl, cyclobutyl or cyclopentyl;

B is an optionally substituted group selected from alkyl, cycloalkyl, aryl, heteroaryl or —NR 2 R 3 , wherein one or more optional substituents on B are selected from halogen, hydroxy, alkyl, haloalkyl, alkoxy, —CO-alkyl, —(CH 2 ) n SO 2 R f or —(CH 2 ) n SO 2 NR c R d ;

R 3 is selected from hydrogen, —(CH 2 ) n —OH, —(CH 2 ) n -cycloalkyl, an optionally substituted groups selected from alkyl, —(CH 2 ) n -heterocyclyl, —(CH 2 ) n -aryl, —(CH 2 ) n -heteroaryl, wherein one or more optional substituents on R 3 are selected from halogen, —CH 2 —OH, alkyl, aryl, —(CH 2 ) n SO 2 NR c R d or —(CH 2 ) n SO 2 R f ;

R 4 is an optionally substituted group selected from alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;

R a is selected from cyano, alkyl, —(CH 2 ) n —OH, —(CH 2 ) n -alkoxy, —CO-alkyl, heteroaryl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f or —(CH 2 )—SO 2 NR c R d ;

R c is hydrogen;

R d and R e are each independently selected from hydrogen, alkyl, alkoxy or aryl, which is optionally substituted with halogen;

R f is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and

n is an integer from 0 to 2.

10 . The compound as claimed in claim 8 , wherein

stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (V) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (V); wherein

R 2 and R 3 combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered cyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO 2 or CO; wherein one or more optional substituents on the heterocyclic ring formed may be selected from halogen, hydroxy, alkoxy, alkyl, cycloalkyl or —CO-alkyl;

R 4 is an optionally substituted group selected from cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, cycloalkyl, alkoxy or —CO-alkyl;

R a is selected from —(CH 2 ) n —OH, —(CH 2 ) n COOR c , —(CH 2 ) n CONR d R e , —(CH 2 ) n SO 2 R f or —(CH 2 ) n SO 2 NR c R d ;

R c is hydrogen;

R d and R e are each independently selected from hydrogen, alkyl or alkoxy;

R f is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and

n in an integer from 0 to 2.

11 . A composition comprising one or more compounds selected from:

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopropane carboxylic acid,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentane carboxylic acid,

1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,

1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[4-(Bis-cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,

1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentanecarboxylic acid,

1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(2-Hydroxy-1-phenyl-ethyl amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{3-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(6-Methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4,4-Difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,

Sodium 1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylate,

{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutyl}-methanol,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid ethylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid dimethylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid tert-butylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid amide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid methoxy-methyl-amide,

1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,

N 4 -tert-Butyl-N 2 -[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid (4-fluoro-phenyl)-amide,

(1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,

N 4 -tert-Butyl-N 2 -[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

N 4 -tert-Butyl-N 2 -[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonylmethyl-cyclobutyl)-phenyl]-amine,

1-[4-(2-tert-Butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-{4-[2-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(6-tert-Butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl)-cyclobutane carboxylic acid,

1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(4-Fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(4-Acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(6-Methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(4-Methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(6-Methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-}4-[2-(1,1-Dioxo-1λ 6 -thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(2-Morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-[4-(4-Isopropoxy-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

12 . The compound as claimed in claim 11 , wherein the compound is:

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-yl-amino)-phenyl]-cyclopropanecarboxylic acid,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentanecarboxylic acid,

1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino]-phenyl]-cyclobutanecarboxylic acid,

1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,

1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[4-(bis-Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,

1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentane-carboxylic acid,

1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutane-carboxylic acid,

1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutane carboxylic acid,

1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino}-phenyl}-cyclobutane carboxylic acid,

1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane-carboxylic acid,

1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

(1-{4-[4-Phenyl-6-((R)-1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-acetic acid,

(1-{4-[4-Phenyl-6-((S)-1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-acetic acid,

1-{4-[4-((S)-2-Hydroxy-1-phenyl-ethylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane-carboxylic acid,

1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutane carboxylic acid,

1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-yl-amino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,

Sodium1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylate,

{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylmethyl)-phenyl]-cyclobutyl}-methanol,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid ethylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid dimethylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid tert-butylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid methoxy-methyl-amide,

1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,

N 4 -tert-Butyl-N 2 -[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid (4-fluoro-phenyl)-amide,

N 4 -tert-Butyl-N 2 -[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

N 4 -tert-Butyl-N 2 -[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine;

stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

13 . The compound as claimed in claim 11 , wherein the compound is

1-{4-[4-(4-fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutane-carboxylic acid,

1-{4-[4-(4-fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutane-carboxylic acid,

1-{4-[4-(1-methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(1-methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{3-[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(6-methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4,4-difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

(1-{4-[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,

[4-(3,5-dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonyl methyl-cyclobutyl)-phenyl]-amine,

stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

14 . The compound as claimed in claim 11 , wherein the compound is

1-[4-(2-tert-butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl}-cyclobutane-carboxylic acid,

1-{4-[2-(tert-butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,

1-[4-(6-tert-butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[6-(3,5-dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,

1-{4-[2-(4-fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(4-acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[6-3,5-dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(6-methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,

1-{4-[2-(4-methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutane carboxylic acid,

1-{4-[2-(6-methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(1,1-dioxo-1λ 6 -thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[6-(3,5-dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(2-morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutanecarboxylic acid,

stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

15 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to claim 1 .

16 . A compound as claimed in claim 1 , wherein the compound is a GATA modulator.

17 . A method for the treatment of atherosclerosis and/or diabetes in a subject, which comprises administering to the subject a therapeutically effective amount of a compound comprising:

stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (I) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (I); wherein,

X, Y and Z are each independently selected from N or CR b , wherein R b is selected from hydrogen, halogen or alkyl; with a proviso that when X and Y are each independently N, Z is —CR b and when Y and Z are each independently N, X is —CR b ;

A is a 3 to 7 membered cycloalkyl ring;

B is an optionally substituted group selected from alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or —NR 2 R 3 , wherein one or more optional substituents on B are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, alkoxy, cycloalkyl, —CO-alkyl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f , —(CH 2 ) n SO 2 NR c R d , aryl, heteroaryl or heterocyclyl;

R 1 is selected from hydrogen or alkyl;

R 2 and R 3 are each independently selected from hydrogen, —(CH 2 ) n -hydroxy, —(CH 2 ) n -halogen, and an optionally substituted group selected from alkyl, —(CH 2 ) n -cycloalkyl, —(CH 2 ) n -heterocyclyl, —(CH 2 ) n -aryl or —(CH 2 ) n -heteroaryl, wherein one or more optional substituents on R 2 and R 3 are each independently selected from halogen, cyano, hydroxy, alkyl, cycloalkyl, alkoxy, —CO-alkyl, —COOR c , —CONR d R e , —(CH 2 ) n SO 2 R f , —(CH 2 ) n SO 2 NR c R d , aryl, heteroaryl or heterocyclyl; or

R 2 and R 3 optionally combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered heterocyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO 2 or CO, wherein one or more optional substituents on the heterocyclic ring are selected from halogen, hydroxy, alkoxy, alkyl, cycloalkyl, or —CO-alkyl;

R 4 is hydrogen or an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R 4 are selected from halogen, hydroxy, cyano, alkyl, —(CH 2 ) n —OH, cycloalkyl, alkoxy or —CO-alkyl;

R a is selected from cyano, —(CH 2 ) n —OH, —(CH 2 ) n -alkoxy, alkyl, aryl, —NH-aryl, heteroaryl, —(CH 2 ) n CO-alkyl, —(CH 2 ) n COOR c , —(CH 2 ) n CONR d R e , —(CH 2 ) n SO 2 R f , or —(CH 2 ) n SO 2 NR c R d ;

R c is selected from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;

R d and R e are each independently selected from hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, alkoxy, aryl, heteroaryl or heterocyclyl, wherein one or more optional substituents on R d and R e are each independently selected from halogen, hydroxy or alkyl;

R f is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; and

n is an integer from 0 to 2.

18 . The method as claimed in claim 17 , comprising treating a subject having diabetes.

19 . The method as claimed in claim 17 , comprising treating a subject having atherosclerosis.

20 . A method for the treatment of atherosclerosis and/or diabetes in a subject, which comprises administering to the subject a therapeutically effective amount of at least one compound selected from one or more of:

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclopropane carboxylic acid,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentane carboxylic acid,

1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,

1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,

1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[4-(Bis-cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,

1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentanecarboxylic acid,

1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,

1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,

1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4- 8 4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(2-Hydroxy-1-phenyl-ethylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,

1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{3-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4-Acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(6-Methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-(4,4-Difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,

Sodium 1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylate,

{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutyl}-methanol,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid ethylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid dimethylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid tert-butylamide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid amide,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid methoxy-methyl-amide,

1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,

N 4 -tert-Butyl-N 2 -[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid (4-fluoro-phenyl)-amide,

(1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,

N 4 -tert-Butyl-N 2 -[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

N 4 -tert-Butyl-N 2 -[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,

[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonylmethyl-cyclobutyl)-phenyl]-amine,

1-[4-(2-tert-Butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-{4-[2-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(6-tert-Butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl}-cyclobutane carboxylic acid,

1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(4-Fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-]2-(4-Acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(6-Methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(4-Methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(6-Methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[2-(1,1-Dioxo-1λ 6 -thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,

1-[4-(2-Morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,

1-[4-(4-Isopropoxy-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,

stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

21 . The method as claimed in claim 20 , comprising treating a subject having diabetes.

22 . The method as claimed in claim 20 , comprising treating a subject having atherosclerosis.